Kornimate/medical-research-clean huggingface dataset:
cervical cerclage for singleton pregnant on vaginal progesterone with progressive cervical length shortening

Conditions: Preterm Labor; Cervical Incompetence

Summary: the aim of this study is to determine whether cerclage with vaginal progesterone will: 1. reduce the overall spontaneous preterm birth rate. 2. prolong pregnancy latency. 3. improve neonatal outcome. compared to vaginal progesterone only, in patients with progressive cervical shortening. research question: does cervical cerclage reduce the overall spontaneous preterm births in patients with progressive cervical shortening. research hypothesis in this current study, the investigators hypothesize that cervical cerclage reduces spontaneous preterm births in patients with progressive cervical shortening on vaginal progesterone only.

a randomized controlled trial the study will be done in ain shams university hospital including women attending antenatal care clinic in ain shams university hospital. all patients entering the trial will be counselled and will sign a written consent explaining the details of the trial. all the patients included in this study will undergo routine fetal anomaly scan at 18-24 weeks.patients with cervical length \< 20 mm in routine anomaly scan will : 1. receive vaginal progesterone suppositories 200 mg daily.. (all patients will be continued with vaginal progesterone until 37 completed weeks or until they develop preterm rupture of membrane or preterm delivery). 2. undergo routine follow up of cervical length every 1 to 2 weeks. patients with progressive shortening of cervical length less than 10 mm during routine follow up, will have the option of continuing vaginal progesterone daily (progesterone 200 mg vaginal suppositories) alone, or having cervical cerclage placed in addition to daily vaginal progesterone. in cerclage group: all patients will sign a written consent for approval of cervical cerclage.

Eligibility criteria:
inclusion criteria: 1. women aged: 20-38 years old. 2. single living fetus. 3. the patient does not have history of preterm labor (before 37 weeks of gestation) 4. no history of cervical or uterine anomalies. exclusion criteria: 1. congenital anomalies in the fetus discovered during the follow up. 2. history of spontaneous preterm births. 3. evidence of imminent delivery, or uterine contractions. 4. evidence of rupture of membranes, or intra amniotic infection. 5. intra uterine fetal death. 6. uterine or cervical anomalies.

Keywords: preterm labor cerclage
development and evaluation of the t.e.a.c.h. study: a randomized control trial

Conditions: Child Obesity

Summary: using a randomized control design, this study seeks to develop and evaluate a nutrition intervention to increase montessori teachers' nutrition knowledge, nutrition self-efficacy, nutrition teaching self-efficacy and cultural food competence to improve teachers' eating behaviors, nutrition teaching practices, classroom food practices, and teacher-parent communication. this study will examine the feasibility and efficacy of a nutrition intervention for teachers which will include a nutrition education program via an online platform and hands-on montessori-based curriculum to teach nutrition in the classroom. teachers from multiple schools will be recruited using the public national montessori listserv. this study will enhance teachers' nutrition knowledge which may increase their nutrition teaching practices and improve their personal nutrition habits. improving teachers' personal and classroom nutrition practices may improve teachers' personal health outcomes and may positively impact their students through modeling of healthy behaviors and improving the classroom food environment.


Eligibility criteria:
inclusion criteria: teachers were considered eligible to participate in the study if they taught in early childhood classrooms (students 3 to 6 years old), were ≥ 18 years old, and had access to an electronic device with internet connection and audiovisual capabilities. exclusion criteria: teachers were deemed ineligible to participate if they were not fluent in english (written \& verbal) or had plans to leave their place of employment during the study timeframe

Keywords: teacher intervention montessori schools obesity prevention nutrition education randomized control trial
regeneration of bronchial epithelium during chronic obstructive pulmonary disease

Conditions: COPD

Summary: airway epithelium integrity is essential to maintain its role of mechanical and functional barrier. recurrent epithelial injuries require a complex mechanism of repair to restore its integrity. in chronic obstructive pulmonary disease (copd), an abnormal airway epithelial repair may participate in airway remodelling. the objective was to determine if airway epithelial wound repair of airway epithelium is abnormal in copd.

patients scheduled for lung resection were prospectively recruited. demographic, clinical data and pulmonary function tests results were recorded. emphysema was visually scored and histological remodelling features were noted. primary bronchial epithelial cells (bec) were extracted and cultured for wound closure assay. the investigators determined the mean speed of wound closure (mswc) and cell proliferation index, matrix metalloprotease (mmp)-2, mmp-9 and cytokines levels in supernatants of bec 18 hours after cell wounding. in a subset of patients, bronchiolar epithelial cells were also cultured for wound closure assay for mswc analyze.

Eligibility criteria:
inclusion criteria: 6 patients scheduled for lung resection for cancer exclusion criteria: * patients with asthma, cystic fibrosis, bronchiectasis or pulmonary fibrosis were excluded
imatinib standard dose (400 mg/day) versus imatinib high dose (800 mg/day)

Conditions: Chronic Myeloid Leukemia

Summary: this is a phase iii multicenter, open-label study designed to investigate the efficacy (hematological response, cytogenetic response and molecular response) and feasibility (tolerance, compliance and safety) of the tyrosine kinase inhibitor imatinib mesylate (formerly sti 571, glivec, novartis pharma) at conventional dose (400 mg/daily) if compared with high dose (800 mg/daily) (serial number protocol icsg/cml/022) in patients with ph+ chronic myeloid leukemia (cml) in chronic phase (cp) previously untreated, at high sokal risk.


Eligibility criteria:
inclusion criteria: 1. age \>/=18 years 2. first chronic phase, less than 6 months of duration 3. high sokal's risk 4. ph positive 5. no previous treatment or hydroxiurea only. 6. performance status (ecog/who) \< 2 7. written informed consent exclusion criteria: 1. age \<18 2. low or intermediate sokal risk score. 3. more than 6 months from diagnosis. 4. second chronic, accelerated or blastic phase 5. scheduled allogeneic stem cell transplantation within 1 year from diagnosis. 6. performance status (ecog/who) \> 2 7. inability to provide written informed consent 8. pregnancy 9. formal refusal of any recommendation of a safe contraception 10. alcohol or drug addiction 11. altered hepatic or renal function as defined by ast/alt or bilirubine \> 3 times upper normal limits (unl) and by creatinine \> 20mg/l 12. any other disease or condition that by the advise of the responsible physician would make the treatment dangerous for the patient or would make the patient ineligible for the study, including physical, psychiatric, social and behavioural problems.

Keywords: chronic myeloid leukemia sti 571 cml022
effects of reciprocal inhibition versus post facilitation muscle energy technique along with conventional physical therapy in patients with piriformis syndrome: a randomized controlled trial

Conditions: Piriformis Syndrome

Summary: this study is a randomized controlled trial and the purpose of this study is to compare the effects of reciprocal inhibition versus post facilitation muscle energy technique along with conventional physical therapy in patients with piriformis syndrome in terms of pain, range of motion at hip joint and functional disability.

this study aims to compare the effects of reciprocal inhibition with post facilitation muscle energy technique along with conventional physical therapy in terms of pain, functional disability and range of motion at hip joint in patients with piriformis syndrome to find the best suitable and effective treatment for it based on the outcomes. males and females between the age of 20-50 years, having buttock pain of ≥ 3 on nprs since 3 months or more and a score of ≥ 8 on a 12-point clinical scoring system as well as any two of the positive screening tests will be recruited in this study as patients of piriformis syndrome. these subjects will be selected via non-probability purposive sampling technique, followed by randomization into two groups using blocked randomization method. a total of 6 treatment sessions will be given to each participant over the duration of 2 weeks with a total of 3 follow-ups after every 2 sessions. tens and hot pack followed by reciprocal inhibition technique will be given to the experimental group a, while the active comparator group b will be given tens and hot pack followed by post-facilitation muscle energy technique. both the groups will be guided about the strengthening exercises given as a home plan.

Eligibility criteria:
inclusion criteria: * age: 20-50 years * both genders * chronic pain in buttock and hip area (≥ 3 on nprs) lasting more than 3 months. * shortened piriformis muscle (internal rotation less than 30°) on muscle length assessment. * a score of ≥ 8 on a 12-point clinical scoring system. * at least two positive screening tests. exclusion criteria: * active infection * lower lumbar radiculopathy * sacroiliac joint dysfunction * malignancies * history of trauma * hip arthroplasty * rheumatoid/ osteoarthritis * any neurological dysfunction
designer dialysis peritoneal dialysis

Conditions: Peritoneal Dialysis; Quality of Life

Summary: this study aims to use modified peritoneal dialysis prescriptions to achieve adequate clearance and volume removal while decreasing the number of exchanges or time spent on dialysis, evaluating maintenance of residual renal function, and improving quality of life.

patient's currently on peritoneal dialysis at our program can be considered for this study. in order to be enrolled, patients patient's must have significant residual renal function defined as a renal kt/v \>1.0. these patients will then be consented, and if agreeable, the participant's dialysis prescriptions will be modified to decrease their peritoneal dialysis. for patients on continuous ambulatory peritoneal dialysis (capd), this may mean less exchanges in a 24 hour period, or less exchanges over the course of the week (does not need to perform exchanges every day). patients who are continuous cycler peritoneal dialysis (ccpd) will be modified to shorter cycler times, or also less cycles during the course of the week (does not need cycler therapy every day). patients will need to continue achieving adequate weekly total kt/v of greater than or equal to 1.7 as per national recommendations and the clinical guidelines within our unit. this is calculated using the residual renal (rr) kt/v and the pd kt/v. patients will also perform monthly 24 hour urine collections for urinary volume, creatinine clearance, and urea clearance. adequacy is typically measured every 3 months based on our internal lab requirements, but patients will need to perform adequacy measurements any time their prescription is changed. the investigators will measure monthly labs per routine including albumin, parathyroid hormone (pth), serum phosphorus, and hemoglobin. the investigators hypothesize that patients will have a better quality of life (qol) while on a modified dialysis prescription with less exchanges or less cycler time as assessed by the kidney disease quality of life (kdqol-36) survey tool. the investigators believe that patients with higher levels of residual renal function (≥ 2 ml/min) can perform fewer peritoneal dialysis exchanges while still achieving and maintaining adequate clearance of solute and appropriate volume removal. the investigators also believe that by maximizing the use of the residual renal function, the investigators can adjust the peritoneal dialysis prescription by decreasing the numbers of manual exchanges per day, decreasing cycler time, or possibly decreasing the number of days of dialysis each week. with the benefit of less dialysis time or exchanges per day, the investigators believe patients will have a decreased "burnout" rate by allowing them to have a better qol and not feel burdened by the dialysis therapy.

Eligibility criteria:
inclusion criteria: * patients on either capd or ccpd and had both residual renal (rr) kt/v ≥ 1.0 and total kt/v values ≥ 1.7. exclusion criteria: * patients who did not meet the values of rr kt/v and total kt/v specified above

Keywords: peritoneal dialysis incremental peritoneal dialysis quality of life end stage renal disease adequacy
analysis of mandibular movements in ventilated children with sleep apnea syndrome

Conditions: Apnea Syndrome; Obstructive Sleep Apnea

Summary: obstructive sleep apnea is a common medical condition in children. diagnosis is based on polysomnography . we conducted an open prospective non randomised clinical trial to assess the efficacy of a new medical device called sunrise.

obstructive sleep apnea affects 4 percent of children. the standard device for the diagnosis and follow up is the polysomnography (psg). however acess for this technique is difficult and expensive in certain institutions . moreover, not all centers are qualified to receive the pediatric population. thus expert consensus is present on the need for the development of a less expensive and easily accessible device to ensure the equality in medical care. recently an innovative medical device utilising the artificial intelligence technology is used to diagnose osa in adults by recording the mandibular movement. martinot et al were the first to use this device in children and noted a correlation between the mandibular movements and polysomnography measurements. a multidisciplinary approach is used in the treatment of osa. indeed, the treatment is based on continous positive pressure and non invasive ventilation. to better evaluate the treatment, the sensor can be an alternative allowing to analyze the mandibular movements without moving at home. we conducted an open prospective non randomised clinical trial to assess the efficacy of a new medical device called "sunrise" in the diagnosis and monitoring of osa.

Eligibility criteria:
inclusion criteria: * children aged 5-18 years inclusive. * with a diagnosis of severe osa diagnosed at psg, defined by an apnoea-hypopnoea index ≥ 10/ hours or an apnoea index ≥ 5/ hours, and associated or not with alveolar hypoventilation. * ventilated with noninvaisve ventilation or continuous positive airway pressure during sleep. * with a nasal or nostril interface. * followed in one of the 2 participating centres: the grenoble-alpes university hospital or the trousseau hospital in paris. exclusion criteria: * patients with centrally-induced sleep apnoea syndrome. * patients at the end of life or for whom limitation of active therapies has been established. * patients ventilated with a naso-oral interface.

Keywords: obstructive sleep apnea apnea syndrome children continuous positive pressure non invasive ventilation
study to compare single dose of three modified release formulations of pf-04937319 with immediate release material-sparing-tablet (ir mst) formulation previously studied in adults with type 2 diabetes mellitus.

Conditions: Type 2 Diabetes Mellitus

Summary: study b1621015 will characterize bioavailability, tolerability and pharmacodynamics of three modified release formulations of pf-04937319 compared with the immediate release material-sparing-tablet (ir mst) formulation in adults with type 2 diabetes.


Eligibility criteria:
inclusion criteria: * adults with type 2 diabetes, on stable background metformin therapy either alone or in combination with another oral anti-diabetic agent (oad) excluding thiazolidinediones (tzds) exclusion criteria: * patients with cardiovascular event within 6 months of screening * patients with diabetic complications * female subjects who are pregnant or planning to become pregnant * subjects with unstable medical conditions (eg, hypertension)

Keywords: phase 1 bioavailability type 2 diabetes mellitus pf-04937319
research and application for new clinical diagnosis and treatment system for hbv related hcc liver transplantation

Conditions: Hepatocellular Carcinoma; Liver Transplantation; Prognosis

Summary: the study evaluated the protein expression levels of fk506-binding protein 12 (fkbp12) in hepatocellular carcinoma (hcc) and paracancerous tissues using immunohistochemistry (ihc). this study aimed to determine the role of fkbp12 in the outcome of liver transplantation recipients with hcc, especially those exceeding the milan criteria. in addition, we explored how sirolimus administration affected lt recipients'prognosis depending on different fkbp12 expression, aiming to provide some advice for clinical sirolimus application after lt.


Eligibility criteria:
inclusion criteria: * (1) pathologically confirmed hcc (2) full post-lt follow-up record exclusion criteria: * (1)sirolimus treatment less than 30 days or after tumor recurrence (2)died within 90 days (3)underwent multiple-organ transplantation
home-based adapted physical activity in anorexia nervosa: a feasibility pilot study

Conditions: Anorexia Nervosa

Summary: the goal of this pilot clinical trial is to assess a program of home-based adapted physical activity in anorexia nervosa.

the main questions it aims to answer are: determining the acceptability of this program / determining the feasibility and safety of this program / determining patient satisfaction / measuring the evolution of the symptomatology. participants will follow a program of home-based adapted physical activity.

Eligibility criteria:
inclusion criteria: * female gender * age between 18 and 60 years * subjects able to give informed consent * eating disorders such as anorexia nervosa * bmi \< 18.5 kg/m2 * affiliated in a social security plan * having given informed consent to the research exclusion criteria: * indication for in-patient care or bmi \< 12 kg/m2 * subject presenting a contrindication to the practice of an adapted physical activity * anorexia nervosa in partial or complete remission for more than 1 year * patient unable, for technical or any other reason, to connect via the internet for tele-monitoring and/or tele-rehabilitation * persons concerned by the articles l1121-5 to l1121-8 of the public health code * subjects who cannot be contacted in case of emergency * subjects in a period of exclusion from another study

Keywords: anorexia nervosa telerehabilitation adapted physical activity
magnesium citrate supplementation on hand grip strength

Conditions: Hand Grasp

Summary: the purpose of this research study is to determine the effectiveness of magnesium on handgrip strength using the more bioavailable magnesium citrate.

in this single-blind, randomized trial, participants will take a daily dose of either 200 or 400 milligrams of magnesium citrate supplement for four weeks, perform three separate handgrip strength tests using a dynamometer, complete a demographics questionnaire, a physical activity questionnaire, and a compliance log.

Eligibility criteria:
inclusion criteria: * generally healthy community adults * individuals age 18 and over * male and female participants exclusion criteria: * individuals currently on magnesium supplements * individuals currently on a multivitamin supplement * individuals who currently suffer from hand pain or hand injury * individuals who currently suffer from arthritis in their hands * individuals suffering from a gastrointestinal disorder complicated by diarrhea, nausea, or abdominal cramping

Keywords: hand grip magnesium citrate
high protein effect on body composition and sarcopenia markers in older patients with type 2 diabetes mellitus

Conditions: Type2 Diabetes Mellitus

Summary: this study will investigate the impact of dietary protein intake on progressive muscle loss and functionality (sarcopenia) in older adults with type 2 diabetes mellitus. sarcopenia is known to have a bidirectional interaction with type 2 diabetes mellitus. therefore in order to address this bidirectional complication we suggest that an increased intake of dietary protein at 1.5 gr/kg/day (current official recommendation is 0.8 gr/kg/day) could help to treat the sarcopenia, which in turn will help to ameliorate the type 2 diabetes mellitus progression.


Eligibility criteria:
inclusion criteria: * must have been diagnosed with type 2 diabetes mellitus during the last 5 years * must have bmi 18.5-24.9 exclusion criteria: * receive dietary supplements * extreme dietary habits * chronic inflammation disease * cancer * autoimmune disease

Keywords: older adults dietary protein nutrition intervention sarcopenia performance oxidative stress inflammation biochemical profile
effects of pravastatin on cholesterol, inflammation and cognition in schizophrenia

Conditions: Schizophrenia; Schizoaffective Disorders; Schizophreniform Disorders

Summary: this study involves people with schizophrenia or schizoaffective disorder, who are currently taking antipsychotic medications. some antipsychotic medications may cause an increase in cholesterol levels, which may lead to inflammation in the body. inflammation poses a risk in developing heart disease, diabetes and problems with brain function. the purpose of this study is to see if pravastatin can: * lower cholesterol * decrease inflammation * improve cognition in patients with schizophrenia

this study is a 12-week randomized, double-blind, placebo-controlled pilot study of pravastatin 40mg a day, administered for 12 consecutive weeks to subjects with schizophrenia to examine pravastatin's effects on lowering cholesterol levels and inflammatory markers, and improving cognition. the study will be conducted at the freedom trail clinic and will use the massachusetts general hospital clinical research center. the innovative approach of using pravastatin to not only decrease cholesterol levels, but to decrease inflammation and improve cognition in patients with schizophrenia is promising and may lead to a different approach to treatment in this population.

Eligibility criteria:
inclusion criteria: * male or female * age 18-68 years * diagnosis of schizophrenia, any subtype, schizoaffective disorder, any subtype or schizophreniform disorder * well established compliance with outpatient medications including their antipsychotic medication exclusion criteria: * inability to provide informed consent * current substance and alcohol abuse * significant medical illness, including congestive heart failure, severe cardiovascular disease, renal disease (serum creatinine \> 1.5), severe hepatic impairment or active liver disease, anemia (hemoglobin \<11.0 gm/dl), history of severe head injury, and not treated muscle disease. * psychiatrically unstable * women of child bearing potential who are pregnant, breastfeeding, or who are unwilling or unable to use an effective form of birth control during the entire study * subjects treated with anti-inflammatory drugs (including daily aspirin and ibuprofen), thiazide diuretics; agents that induce weight loss, and st. john's wort will be excluded from the study * current history of untreated thyroid disease * current treatment with insulin * subjects being treated with drugs such as: colchicine, azole antifungals (fluconazole, ketoconazole, itraconazole); macrolide antibiotics (clarithromycin, erythromycin); hiv protease inhibitors (ritonavir, indinavir, saquinavir, nelfinavir) that inhibit the cyp 450 3a liver enzyme * known hypersensitivity to pravastatin or any of its components

Keywords: schizophrenia pravastatin inflammation cognition antipsychotics cholesterol